Equities Analysts Offer Predictions for TG Therapeutics, Inc.’s FY2025 Earnings (NASDAQ:TGTX)

TG Therapeutics, Inc. (NASDAQ:TGTX) – Stock analysts at HC Wainwright dropped their FY2025 earnings estimates for shares of TG Therapeutics in a research note issued on Thursday, May 2nd. HC Wainwright analyst E. White now anticipates that the biopharmaceutical company will earn $0.11 per share for the year, down from their prior forecast of $0.19. HC Wainwright has a “Buy” rating and a $49.00 price target on the stock. The consensus estimate for TG Therapeutics’ current full-year earnings is ($0.11) per share. HC Wainwright also issued estimates for TG Therapeutics’ FY2026 earnings at $0.49 EPS.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.02). TG Therapeutics had a net margin of 14.24% and a return on equity of 33.79%. The business had revenue of $63.47 million for the quarter, compared to analysts’ expectations of $54.60 million. During the same quarter in the previous year, the firm earned ($0.28) EPS. TG Therapeutics’s revenue was up 713.5% compared to the same quarter last year.

Several other equities research analysts have also recently issued reports on TGTX. LADENBURG THALM/SH SH boosted their price objective on shares of TG Therapeutics from $39.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday, May 2nd. JPMorgan Chase & Co. reiterated an “overweight” rating and issued a $25.00 price target on shares of TG Therapeutics in a report on Thursday, April 18th. The Goldman Sachs Group increased their price objective on TG Therapeutics from $12.00 to $13.00 and gave the stock a “neutral” rating in a research note on Thursday, February 29th. B. Riley lifted their target price on TG Therapeutics from $24.00 to $29.00 and gave the company a “buy” rating in a research report on Monday, February 5th. Finally, StockNews.com downgraded TG Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, February 24th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $29.83.

TG Therapeutics Stock Up 4.1 %

Shares of TGTX opened at $17.18 on Monday. The firm has a market capitalization of $2.65 billion, a P/E ratio of 74.70 and a beta of 2.33. TG Therapeutics has a 12-month low of $6.46 and a 12-month high of $35.22. The firm has a fifty day moving average price of $15.38 and a 200-day moving average price of $14.66. The company has a current ratio of 5.92, a quick ratio of 5.18 and a debt-to-equity ratio of 0.62.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the company. Vanguard Group Inc. grew its holdings in TG Therapeutics by 1.5% in the fourth quarter. Vanguard Group Inc. now owns 13,670,944 shares of the biopharmaceutical company’s stock worth $233,500,000 after purchasing an additional 199,770 shares during the last quarter. Wellington Management Group LLP grew its stake in TG Therapeutics by 1.4% during the 4th quarter. Wellington Management Group LLP now owns 3,139,764 shares of the biopharmaceutical company’s stock worth $53,627,000 after buying an additional 43,290 shares during the last quarter. Opaleye Management Inc. increased its position in TG Therapeutics by 17.2% during the 4th quarter. Opaleye Management Inc. now owns 2,215,000 shares of the biopharmaceutical company’s stock valued at $37,832,000 after buying an additional 325,000 shares in the last quarter. Schonfeld Strategic Advisors LLC raised its stake in TG Therapeutics by 164.5% in the third quarter. Schonfeld Strategic Advisors LLC now owns 1,367,400 shares of the biopharmaceutical company’s stock valued at $11,431,000 after buying an additional 850,507 shares during the last quarter. Finally, 683 Capital Management LLC purchased a new stake in TG Therapeutics in the third quarter valued at about $11,286,000. Hedge funds and other institutional investors own 58.58% of the company’s stock.

Insiders Place Their Bets

In other news, Director Laurence N. Charney sold 22,000 shares of TG Therapeutics stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $15.97, for a total value of $351,340.00. Following the transaction, the director now directly owns 215,229 shares in the company, valued at approximately $3,437,207.13. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 9.20% of the stock is owned by company insiders.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.